OR WAIT null SECS
Singapore facility delivers manufacturing redundancy and increases supply assurance for global biologic drug discovery and production.
Thermo Fisher Scientific Inc. announced it is expanding its global cell culture and bioprocessing capabilities by opening a new manufacturing plant in Singapore to produce dry powder media (DPM),a crucial cell culture raw material used to manufacture biologics, including vaccines, anticancer therapeutics, and others. The facility is the first cell culture DPM production site in Singapore and is designed to address the increased global requirements from biopharmaceutical companies to mitigate critical raw material supply risks, the company reports.
Located in Tuas, the 30,800 ft2 facility will provide manufacturing redundancy of DPM to help ensure a secure and uninterrupted supply to biopharmaceutical customers globally, according to a company statement. The facility will also serve as an additional logistics hub for DPM distribution to Asia Pacific customers.
Featuring state-of-the-art pin milling technology, the new Singapore DPM facility is a cGMP manufacturing plant, mirroring the functionality and quality systems used in Thermo Fisher’s DPM facility in the United States.
Source: Thermo Fisher Scientific